- Home
- TCRX vs CODA Comparison
TCRX vs CODA Comparison
Compare TCRX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- CODA
- Stock Information
- Founded
- TCRX 2018
- CODA 1994
- Country
- TCRX United States
- CODA United States
- Employees
- TCRX N/A
- CODA N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- CODA Industrial Machinery/Components
- Sector
- TCRX Health Care
- CODA Industrials
- Exchange
- TCRX Nasdaq
- CODA Nasdaq
- Market Cap
- TCRX 91.7M
- CODA 88.8M
- IPO Year
- TCRX 2021
- CODA N/A
- Fundamental
- Price
- TCRX $1.60
- CODA $8.30
- Analyst Decision
- TCRX Strong Buy
- CODA Strong Buy
- Analyst Count
- TCRX 5
- CODA 1
- Target Price
- TCRX $9.40
- CODA $11.00
- AVG Volume (30 Days)
- TCRX 219.1K
- CODA 79.4K
- Earning Date
- TCRX 11-11-2025
- CODA 09-15-2025
- Dividend Yield
- TCRX N/A
- CODA N/A
- EPS Growth
- TCRX N/A
- CODA 15.09
- EPS
- TCRX N/A
- CODA 0.30
- Revenue
- TCRX $6,961,000.00
- CODA $24,347,217.00
- Revenue This Year
- TCRX $255.18
- CODA $30.82
- Revenue Next Year
- TCRX N/A
- CODA $20.84
- P/E Ratio
- TCRX N/A
- CODA $27.50
- Revenue Growth
- TCRX N/A
- CODA 29.34
- 52 Week Low
- TCRX $1.02
- CODA $5.76
- 52 Week High
- TCRX $6.23
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- TCRX 36.40
- CODA 55.98
- Support Level
- TCRX $1.73
- CODA $7.85
- Resistance Level
- TCRX $1.96
- CODA $8.80
- Average True Range (ATR)
- TCRX 0.11
- CODA 0.40
- MACD
- TCRX -0.03
- CODA 0.02
- Stochastic Oscillator
- TCRX 0.00
- CODA 57.98
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.